EMID2 is a novel biotherapeutic for aggressive cancers identified by in vivo screening

Abstract Background New drugs to tackle the next pathway or mutation fueling cancer are constantly proposed, but 97% of them are doomed to fail in clinical trials, largely because they are identified by cellular or in silico screens that cannot predict their in vivo effect. Methods We screened an Ad...

Descrición completa

Detalles Bibliográficos

Principais autores:	Ambra Cappelletto, Edoardo Alfì, Nina Volf, Thi Van Anh Vu, Francesca Bortolotti, Giulio Ciucci, Simone Vodret, Marco Fantuz, Martina Perin, Andrea Colliva, Giacomo Rozzi, Matilde Rossi, Giulia Ruozi, Lorena Zentilin, Roman Vuerich, Daniele Borin, Romano Lapasin, Silvano Piazza, Mattia Chiesa, Daniela Lorizio, Luca Triboli, Sandeep Kumar, Gaia Morello, Claudio Tripodo, Maurizio Pinamonti, Giulia Maria Piperno, Federica Benvenuti, Alessandra Rustighi, Hanjoong Jo, Stefano Piccolo, Giannino Del Sal, Alessandro Carrer, Mauro Giacca, Serena Zacchigna
Formato:	Artigo
Idioma:	Inglês
Publicado:	BMC 2024-01-01
Series:	Journal of Experimental & Clinical Cancer Research
Assuntos:	In vivo screening Cancer Cell invasiveness AAV vectors Gene therapy Biotherapeutics
Acceso en liña:	https://doi.org/10.1186/s13046-023-02942-4
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!